Asmax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asmax

Property Description
Active Ingredient Ketotifen Fumarate
Forms Tablets, Syrup, Ophthalmic Solution
Pharmacological Class Antihistamine and Mast Cell Stabilizer
General Purpose Prophylaxis of chronic allergic conditions
Origin Synthetic Compound

Asmax (Ketotifen Fumarate): Definition and Origin

Asmax is a synthetic medicine defined by its active ingredient, Ketotifen Fumarate, which is used for the long-term management of chronic allergic processes. The medicine functions as a dual-acting anti-allergic agent, classified as both a relatively selective histamine H1-receptor antagonist and a potent mast cell stabilizer. Ketotifen is a synthetic compound, specifically a benzocycloheptathiophene derivative, and is recognized within the pharmacological community as a non-bronchodilator antiasthmatic for systemic use. The compound functions in a dual role by both blocking histamine and preventing its release from mast cells.

Composition and Available Forms of Asmax

The core composition of Asmax features Ketotifen Fumarate as the single active ingredient product, responsible for all its therapeutic effects. The medicine is formulated for both systemic use via the oral route and localized topical use applied to the eye. For internal use, it is available as tablets and a liquid syrup, which is often utilized for pediatric patients. The ophthalmic solution (eye drops) is primarily utilized for topical ocular administration in cases of allergic conjunctivitis. Ophthalmic formulations of Ketotifen are categorized as an anti-allergic agent specifically intended for ocular relief.

General Therapeutic Role and Purpose

The overarching purpose of Asmax is to serve as a prophylactic (preventive) medicine for chronic allergic conditions, aiming to provide continuous support against recurrent allergic episodes. Unlike relief medications intended to stop immediate, acute symptoms, the primary therapeutic role of this medicine is to maintain a long-term reduction in the body’s hyper-reactivity to allergens. By stabilizing key immune cells and blocking histamine, the medicine functions to lessen the overall frequency and severity of allergic manifestations over a sustained period of time, offering comprehensive control over chronic allergic symptoms.

What side effects are possible with Asmax?

Possible Side Effects and Safety Information

The safety profile of Asmax (Ketotifen Fumarate) is organized by regulatory authorities into System-Organ Classes and frequency categories, documenting adverse reactions observed in clinical use. Common adverse reactions typically involve the nervous system and psychiatric disorders, and certain effects are noted to occur predominantly at the start of treatment.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency as defined in regulatory documents:

  • Common: Agitation, irritability, insomnia, nervousness (particularly in children), and weight gain.
  • Uncommon: Dizziness and dry mouth.
  • Rare: Sedation.

Systemic Safety Considerations

Side effects are primarily observed in the Nervous System (e.g., somnolence, headache, dizziness) and Gastrointestinal Disorders (e.g., dry mouth, nausea). Furthermore, the official label documents Severe Cutaneous Adverse Reactions (SCARs), including Erythema multiforme and Stevens-Johnson syndrome, which are classified as Very Rare.

Safety constraints and population-specific notes are also defined in regulatory labeling:

  • Time-Related Pattern: Sedation, somnolence, dry mouth, and dizziness may manifest at the beginning of treatment but are typically documented to disappear spontaneously with continued use.
  • Safety Restrictions: The systemic use of Ketotifen Fumarate is contraindicated during breastfeeding. Furthermore, official regulatory documents state that co-administration with oral antidiabetic agents is to be avoided due to reports of reversible thrombocytopenia.
  • Specific Caution: The medicine should be used with caution in individuals with a history of epilepsy due to the possibility of lowering the seizure threshold.

Overdose and Emergency Response

The official regulatory documentation for Ketotifen Fumarate (Asmax) defines the overdose profile primarily through effects on the Central Nervous System (CNS) and cardiovascular function, based on documented ingestion of large amounts.

Overdose Manifestations Severe Outcomes
Drowsiness, Somnolence Reversible Coma
Confusion, Disorientation Convulsions, Apnea
Tachycardia, Hypotension Hyperexcitability (in children)

The clinical presentation typically begins with CNS symptoms such as marked drowsiness, which may progress to confusion and disorientation. More severe outcomes, which define the escalation of risk, include the development of reversible coma, alongside cardiovascular effects like tachycardia and hypotension.

Emergency Action and Management

In the event of a suspected overdose, immediate medical attention must be sought as mandated by regulatory authorities. The official information describes the management as symptomatic and supportive treatment, since no specific antidote is known for Ketotifen Fumarate. Following ingestion, official procedural guidance may include measures such as gastric lavage or administration of activated charcoal. Hospital monitoring of the cardiovascular and CNS systems is required for stabilization.

Population-specific notes highlight that pediatric patients may exhibit heightened risk, presenting with hyperexcitability and convulsions as documented primary signs.

Therapeutic Uses of Asmax

What Asmax Treats: Main Uses and Benefits

As a prophylactic agent, Asmax is considered relevant when supportive symptom management is appropriate for long-term chronic conditions. The medicine is utilized in the therapeutic areas of asthma and systemic mast cell conditions. The medication is commonly used to help with long-term prophylactic management of conditions characterized by periods of heightened symptoms, such as mild to moderate bronchial asthma and persistent wheezing. It is also relevant for easing symptoms associated with chronic urticaria (hives) and allergic conjunctivitis.

The core benefit may be providing support that helps ease the overall symptom burden by assisting with managing symptoms related to episodic or fluctuating manifestations. In specialized cases, the medicine is applied in addressing symptom clusters that interfere with daily functioning, supporting the patient during difficult episodes by easing distressing manifestations, including recurring skin symptoms and specific gastrointestinal distress.

“The medicine is applied in addressing symptom clusters that interfere with daily functioning, and may assist with managing symptoms that create noticeable physiological strain.”

The topical form may assist with managing symptoms related to physical discomfort like intense eye itching, redness, and swelling, which contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Recurrent Symptoms
Primary Therapeutic Goal: Prophylactic control to support patients during episodes of heightened discomfort associated with recurrent symptoms.

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Asmax

Regulatory documentation establishes specific population boundaries for the use of systemic Ketotifen Fumarate (Asmax).

Contraindications

Use is strictly contraindicated for individuals with known hypersensitivity to the drug or its excipients, patients with established epilepsy, and those receiving concurrent treatment with oral antidiabetic agents. The systemic oral formulation is also contraindicated for breastfeeding mothers.

Age and Life Stage Restrictions

Eligibility is established for adults and adolescents. For the oral formulation, use is approved for children aged 3 years and above, though it is a restricted population for children under two years. For the ophthalmic solution, safety and effectiveness have not been established for children below the age of three years. In pregnancy, safety is not established, and use is only recommended in compelling circumstances.

Condition-Specific Limitations

Patients with hepatic impairment (liver function issues) or renal impairment (kidney function issues) are populations with restricted use, as regulatory agencies report a lack of specific studies, meaning no official dosing recommendations can be provided for these groups. Caution is also advised for patients with a history of epilepsy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Asmax (Ketotifen Fumarate)'s official interaction profile is defined by restrictions on co-administration and documented pharmacodynamic consequences, as stated in authoritative government prescribing information.


Interaction Scope

Property Value
Medicinal product categories with documented interactions: Sedatives, Hypnotics, Other Antihistamines, Oral Antidiabetic Agents (Oral Hypoglycemic Agents).
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic (PD) potentiation.
Timing-based interaction rules (if applicable): Ophthalmic solution requires removal of soft contact lenses and a wait time of at least ten minutes before reinsertion.
Population-specific interaction notes (if applicable): The syrup formulation’s carbohydrate content must be considered in patients with Diabetes mellitus.

Interaction Classifications (High-Level)

Classification Value
Interaction severity classification (as defined in official documents): Contraindicated combination (with Oral Antidiabetic Agents); Significant Potentiation (with CNS depressants/Alcohol).
Interaction-context constraints (as defined in official documents): Co-administration with Oral Antidiabetic Agents is linked to a reversible fall in the thrombocyte count.

Official Interaction Statements

  • Co-administration with Oral Antidiabetic Agents is contraindicated due to the documented risk of a reversible fall in the thrombocyte count.
  • Pharmacodynamic potentiation is documented with sedatives, hypnotics, other antihistamines, and Alcohol, increasing the risk of central nervous system (CNS) depression.
  • The ophthalmic solution requires procedural separation from soft contact lenses and other eye medications.

Connection to the overall interaction profile

Government regulatory documents establish the drug's interaction profile around two primary domains: a mandatory restriction against co-administering with Oral Antidiabetic Agents and caution regarding PD potentiation with CNS depressants. These statements precisely define the necessary limits and effects of co-administration as determined by official authorities.

Mechanism of Action

Asmax is a pharmaceutical product containing the active ingredient montelukast, which functions as a selective cysteinyl leukotriene receptor 1 (CysLT1) antagonist. The drug concentrates primarily in tissues involved in the inflammatory cascade, including the airways. Its primary biological target is the CysLT1 receptor, a G-protein-coupled receptor, which is expressed on the surface of inflammatory cells and smooth muscle cells.

Montelukast binds with high affinity to the CysLT1 receptor, competitively inhibiting the binding of pro-inflammatory cysteinyl leukotrienes, specifically leukotriene D4 (LTD4), to this receptor. This competitive antagonism blocks the molecular and intracellular signaling cascade normally initiated by LTD4 binding, which involves Gq protein activation leading to an increase in intracellular calcium concentration. The downstream cascade of this inhibition prevents the activation of pathways responsible for cellular migration, mucus secretion, and the proliferation of smooth muscle cells. The system-level physiological consequence of CysLT1 blockade is the modulation of bronchoconstriction and the attenuation of pro-inflammatory cellular activity within the respiratory system.

Dosage and Administration Information

Administration instructions for Asmax (referring to either Montelukast or Mometasone Furoate formulations) are based on the specifications for each active ingredient and must be followed precisely.

Administration Scope

Feature Montelukast (Oral) Mometasone Furoate (Inhalation)
Route of administration Oral route only. Orally inhaled route only.
Dosing schedule Once daily, dose varies by age (e.g., 10 mg for age 15 years, 4 mg for 2 to 5 years). Twice daily (HFA) or Once daily (Twisthaler), dose varies by age/prior therapy.
Timing in relation to meals Can be taken with or without food. Not specified in relation to food.

Preparation and Procedural Rules

Montelukast (Oral Granules) must be administered within 15 minutes of opening the sachet. The granules may be swallowed directly or mixed with 5 mL of cold/room temperature soft food (e.g., applesauce, rice) or formula. The mixed dose must not be stored.

Mometasone Inhalation Aerosol requires priming the inhaler with 4 test sprays if it is new or has not been used for more than 5 days. The inhaler must be shaken well before each inhalation. Immediately after administration, the patient must rinse the mouth with water and spit out the contents to reduce localized effects.

Missed and Exercise Doses

If a dose of either medicine is missed, the patient must take the next scheduled dose at the regular time; do not take two doses to make up for the missed dose. For Montelukast taken for exercise prevention, the dose should be taken at least 2 hours before exercise, and an additional dose must not be taken within 24 hours of the previous dose. The inhaled products are not indicated for use as a rescue inhaler for acute symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Asmax

Research Evidence for Prophylaxis of Chronic Allergic Conditions (Oral Use)

Studies exploring the use of Asmax for managing chronic bronchial asthma and persistent wheezing primarily involved short- to intermediate-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. Research focused on the pediatric population, including children diagnosed with mild to moderate chronic conditions. These investigations monitored outcomes related to physical discomfort, specifically measuring changes in asthma symptom scores, the frequency of acute episodes, and the daily use of rescue inhalers over defined time intervals.

Research describes that some studies reported measurements that indicated an association between use and changes in these symptom severity scores over periods of up to four months. However, the evidence remains heterogeneous; reported outcomes reflecting daily functioning or activity level varied across studies. Long-term effects are not fully established, and the existing studies provide limited insight into the medicine’s outcomes when compared to modern, first-line inhaled standard-of-care treatments for asthma.

Research Evidence for Allergic Conjunctivitis (Topical Use)

The topical formulation of Asmax was evaluated in numerous, consistent Randomized Controlled Trials (RCTs) and specialized studies. Research was conducted in adults and children with confirmed allergic conjunctivitis, a population relevant in trials assessing short-term or episodic symptom patterns.

The research examined outcomes related to physical discomfort, mainly measuring the severity of ocular itching (pruritus), alongside signs like conjunctival redness and eyelid swelling. RCTs reported measurements that documented changes in ocular itching scores when compared to placebo across various time points. The existing evidence is derived from a high volume of short-term studies focusing on symptom endpoints, but there is limited information for long-term outcomes.

What is Still Uncertain About Asmax Research

Research provides context regarding patient experience and symptom evolution, while also pointing to certain limitations in the available data. Comparative evidence is lacking for direct comparison against newer, widely accepted treatment standards across all indications. Findings were often mixed or inconsistent across studies, particularly when outcomes related to physical signs were monitored instead of patient-reported symptoms. Because long-term effects are not fully established and follow-up durations were limited, the overall certainty remains low regarding the ultimate long-term outcomes over years of use.

Key Studies & References

  1. Review of Ketotifen's Profile in Clinical Practice (General Uses and Mechanism)

Frequently Asked Questions (FAQ)

Common questions about Asmax (FAQ)


Q: Does Asmax start working right away?

Official documents describe Asmax as a prophylactic (preventative) medicine intended for long-term control rather than immediate relief. Studies and product information indicate that the full preventative effect may take several weeks of continuous administration to become apparent.


Q: How long do the effects of Asmax last?

Pharmacokinetic data from regulatory sources, which describes how the medicine is processed by the body, indicates the oral formulation has an elimination half-life of approximately 22 hours. This duration of effect is consistent with the drug’s intended use for maintaining continuous preventative support.


Q: What should I do if I accidentally miss a time to use Asmax?

Official regulatory documents typically describe that if a dose is missed, patients are instructed to take the dose when remembered, unless it is nearly time for the next scheduled dose. Guidance states that a double dose should not be taken to compensate for a missed time.


Q: What kind of studies support the use of Asmax?

Regulatory documents and research overviews cite evidence that primarily comes from short- to intermediate-term Randomized Controlled Trials (RCTs) in the intended populations. These studies were generally focused on monitoring outcomes such as changes in patient-reported symptom scores and the use of relief medications.


Q: What does it mean if an official document says Asmax is a 'maintenance' treatment?

The term 'maintenance treatment' means the medicine is intended for continuous, long-term preventative use to help manage chronic allergic conditions. Official documents emphasize that Asmax is designed to be part of a long-term strategy and is not intended for the immediate relief of sudden, acute symptoms.


Q: How is the safety profile of Asmax documented?

The official safety profile is documented in regulatory labeling by listing observed adverse reactions. These effects are organized according to the body system they affect and are classified based on their frequency of occurrence, which is determined from clinical trials and ongoing monitoring.


Q: Is Asmax addictive?

Official drug classification documents state that the active ingredient, Ketotifen Fumarate, is not classified as a controlled substance. This classification indicates that the medicine is not regulated as a substance with a high potential for abuse or dependence.


Q: Is Asmax the same as other breathing medications I see advertised?

Asmax is defined by regulatory bodies as a dual-acting anti-allergic agent that works as both a histamine blocker and a mast cell stabilizer. It is officially classified as a non-bronchodilator antiasthmatic for systemic use, meaning its function and pharmacological class are distinct from many other types of breathing medications.


Q: Will Asmax affect my sleep?

Official labeling lists both insomnia (difficulty sleeping) and sedation (drowsiness) as possible adverse reactions. These effects, along with nervousness, are sometimes noted at the start of treatment but are typically documented to spontaneously lessen or disappear with continued use.


Q: Is Asmax considered a steroid?

No. Official drug classifications state that the active ingredient, Ketotifen Fumarate, is a Histamine H1-receptor Antagonist and a Mast-cell Stabilizer. It is not classified as a corticosteroid or steroid medication.


Q: Is Asmax safe to use during pregnancy?

Official regulatory guidance states that use is generally recommended only in compelling circumstances. Official documents note that safety in humans is not established, and use is generally recommended only in situations where the potential benefit is considered to justify the potential risk.


Q: How does Asmax fit into a long-term treatment plan?

Asmax is intended to be a prophylactic agent taken continuously as part of a patient's long-term management strategy. Its purpose is to maintain a sustained reduction in the frequency and severity of chronic allergic episodes over time.


Q: Are there any long-term effects of using Asmax for many years?

Reviews of existing research evidence indicate that long-term effects are not fully established because follow-up durations in studies have been limited. This means there is not extensive data to describe outcomes over many years of continuous use.


Q: Can elderly patients use Asmax?

Official dosing guidelines establish use for adults and adolescents. Regulatory labeling does not contain specific restrictions or modified dosing instructions unique to the geriatric (elderly) population, but medical factors may require individualized consideration.


Q: Is there a generic version of Asmax available?

Yes, the active ingredient in Asmax, Ketotifen Fumarate, is available in generic form for some marketed formulations. This includes certain formulations like the ophthalmic solution, depending on the region.


Q: Is it normal to have a dry mouth after using Asmax?

According to official safety labeling, dry mouth is documented as an Uncommon adverse reaction. This means it may be reported in a small percentage (between 0.1% and 1%) of patients in clinical settings.


Q: Will Asmax affect my ability to drive or operate machinery?

Official warnings state that the medicine may cause some people to become drowsy, dizzy, or less alert. Users are advised to be aware of how they react to the medication before attempting to drive or operate machinery.


Q: What is the typical length of treatment with Asmax?

The medicine is intended for long-term control. While the overall duration is determined by medical professionals, research evidence often describes studies where changes in symptoms were monitored over periods of up to four months to assess its preventative effect.


Q: Does Asmax contain lactose or gluten?

Official documents confirm that the oral tablet formulation of Asmax contains lactose monohydrate as an inactive ingredient (excipient). The composition of other forms, such as the syrup or eye drops, varies.


Q: Is there a specific time of day Asmax should be used?

For the oral formulation, the usual use is documented as twice daily, often separated into a morning and an evening application to help maintain consistent preventative support.


Q: How are the side effects of Asmax usually managed?

The official label documents that common nervous system side effects, such as sedation, drowsiness, and dizziness, may occur when treatment begins. These effects are typically described in official documents to disappear spontaneously with continued use of the medicine.


Q: Why do official guidelines mention monitoring certain health markers while on Asmax?

Official guidelines recommend caution and monitoring, particularly when the medicine is used at the same time as Oral Antidiabetic Agents. This is due to the documented potential for a reversible fall in the thrombocyte count (thrombocytopenia), which is a condition involving platelet levels in the blood.

How should Asmax be stored and disposed of?

How to Store and Dispose of Asmax? — Official Regulatory Requirements

Official regulatory documentation provides specific requirements for storing and disposing of this medication to maintain its stability and ensure safety.

Storage Conditions

Requirement Classification/Detail
Temperature Store at 25 C (77 F); excursions permitted between 15 C and 30 C.
Protection Store in the original package to protect from both light and moisture (e.g., humidity).
Child Safety Keep this and all medications out of the reach of children.

Handling and Stability

For the oral granule formulation, once the packet is opened or the contents are mixed with a spoonful of soft food, the medication must be taken within 10 to 15 minutes.

Disposal

Expired or unused medication must be disposed of according to local, state, and federal regulations. Official guidance for destruction may recommend methods such as incineration at an approved facility. Environmental release, such as discharge into drains or water courses, must be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Asmax found in:

A-Z Index: